|Idera Pharmaceuticals, Inc.|
167 Sidney Street
United States - Map
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. The companys lead drug candidates in TLR program includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of various autoimmune diseases, such as moderate to severe plaque psoriasis, polymyositis, dermatomyositis, Waldenströms macroglobulinemia, and diffuse large B-cell lymphoma; and IMO-9200 that is in preclinical studies that supports the submission of an investigational new drug application to the United States Food and Drug Administration. It is also involved in the initiation of research program that employs gene silencing oligonucleotides to inhibit the production of disease-associated proteins by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; license and research collaboration agreement with Merck Sharp & Dohme Corp. to develop and commercialize TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimers disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
|Dr. Sudhir Agrawal D. Phil,
Chief Exec. Officer, Pres and Director
|Mr. Louis J. Arcudi III, MBA,
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Operations, Sec. and Treasurer
|Dr. Timothy M. Sullivan Ph.D.,
VP of Devel. Programs & Alliance Management
|Dr. Robert David Arbeit M.D.,
VP of Clinical Devel.
|Dr. Louis Brenner M.D.,
Chief Medical Officer and Sr. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|